SCHEMBL2950895

SCHEMBL2950895

COc1ccc(-c2nc3c(C(=O)O)cc(Br)cc3o2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
MAPT P10636 4/20 0.57
NPC1 O15118 4/20 0.57
RAB9A P51151 4/20 0.57
KDM4E B2RXH2 3/20 0.57
HPGD P15428 2/20 0.57
KMT2A Q03164 2/20 0.57
MEN1 O00255 1/20 0.57
MAPK1 P28482 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
HDAC6 Q9UBN7 2/20 0.51
THRB P10828 1/20 0.46
GPR35 Q9HC97 2/20 0.46
MCL1 Q07820 1/20 0.46
IKBKB O14920 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HSD17B10 Q99714 1/20 0.44
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2953614 0.86 MAPT (0.50) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL2964683 0.85 MAPT (0.47) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL2954868 0.84 RAB9A (0.54) ALDH1A1NPC1RAB9AKDM4EHPGD
SCHEMBL2957072 0.82 TOP2A (0.59) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL2957123 0.82 TOP2A (0.53) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL3032061 0.80 TOP2A (0.63) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL2957781 0.76 HTR3A (0.57) HTR3A
SCHEMBL5247114 0.75 HTR3A (0.47) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL1387272 0.74 PARP1 (0.58) ALDH1A1MAPTNPC1RAB9AKDM4E
SCHEMBL2954779 0.74 TOP2A (0.70) ALDH1A1MAPTNPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781430-B2 Benzoxazole carboxamides for treating CINV and IBS-D ALBANY MOLECULAR RESEARCH, INC. (US) 2010-08-24 US disclosed
US-20080108609-A1 Benzoxazole Carboxamides For Treating CINV and IBS-D AMR TECHNOLOGY, INC. (US) 2008-05-08 US disclosed
US-7307094-B2 Benzoxazole carboxamides for treating CINV and IBS-D AMR TECHNOLOGY, INC. (US) 2007-12-11 US disclosed
EP-1853597-A1 BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D AMR Technology, Inc. (US) 2007-11-14 EP disclosed
WO-2006089100-A1 BENZOXAZOLE CARBOXAMIDES FOR TREATING CINV AND IBS-D AMR TECHNOLOGY, INC. (US) 2006-08-24 WO disclosed
US-20060183769-A1 Benzoxazole carboxamides for treating CINV and IBS-D AMR TECHNOLOGY, INC. (US) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108609-A1 Benzoxazole Carboxamides For Treating CINV and IBS-D HTR3E, BRS3, HTR3A ALDH1A1 3208/4885MAPT 4376/4885NPC1 3320/4885
US-20060183769-A1 Benzoxazole carboxamides for treating CINV and IBS-D HTR3E, BRS3, HTR3A ALDH1A1 3208/4885MAPT 4376/4885NPC1 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.